These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 1956210

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The disposition of antituberculous drugs in plasma of elderly patients. I. Isoniazid and hydrazine metabolite.
    Walubo A, Chan K, Woo J, Chan HS, Wong CL.
    Methods Find Exp Clin Pharmacol; 1991 Oct; 13(8):545-50. PubMed ID: 1956209
    [Abstract] [Full Text] [Related]

  • 3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC, Lee YC.
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
    Acocella G, Luisetti M, Grassi GG, Peona V, Pozzi E, Grassi C.
    Monaldi Arch Chest Dis; 1993 Jun; 48(3):205-9. PubMed ID: 8369784
    [Abstract] [Full Text] [Related]

  • 10. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.
    Int J Pharm; 2004 May 19; 276(1-2):41-9. PubMed ID: 15113612
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O, Haegi V, Villiger B, Bohn W, Baumann HR, Zäch R.
    Schweiz Med Wochenschr; 1989 Mar 11; 119(10):299-305. PubMed ID: 2652281
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM, Goldberg SV.
    Int J Tuberc Lung Dis; 2002 Nov 11; 6(11):952-8. PubMed ID: 12475140
    [Abstract] [Full Text] [Related]

  • 17. Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess.
    Jutte PC, Rutgers SR, Van Altena R, Uges DR, Van Horn JR.
    Int J Tuberc Lung Dis; 2004 Nov 11; 8(11):1368-72. PubMed ID: 15581207
    [Abstract] [Full Text] [Related]

  • 18. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekaran V, Kumaraswami V, Prabhakar R.
    Int J Tuberc Lung Dis; 1999 Feb 11; 3(2):119-25. PubMed ID: 10091876
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.